PDF
Full
Outline
To systematically evaluate the efficacy and safety of lecarnitine in the treatment of patients with myocardial damage.
Search databases such as PubMed, Embase, Cochrane Library, CNKI, Wanfang Database, etc. randomized controlled trials (RCTS) comparing L-carnitine with sodium creatine phosphate, sodium fructobisphosphonate, trimetazidine and coenzyme Q10 for the treatment of myocardial damage were included according to the inclusion and exclusion criteria. The search period for all was from the establishment of the database to May 2024. Meta-analysis was performed using RevMan 5.3 and Stata 14.0.
A total of 12 RCTs were included, involving a total of 1 408 patients. Meta-analysis showed that the total effective rate of levocarnitine was 89.53% (556 cases/621 cases), which was significantly higher than that [83.98% (519 cases/618 cases)]of the control group [OR=1.83, 95% CI (1.10~3.06), P<0.05]; the incidence of adverse drug reactions of levocarnitine and the control group was 2.47% (9 cases/364 cases) and 3.31% (12 cases/362 cases) with no statistically significant difference [OR=0.83, 95% CI (0.17~4.18), P>0.05]. The creatine kinase (CK) levels of L-carnitine group and the control group were(203.04±34.59) and (238.28±33.97)U·L-1, respectvely [OR=-26.81, 95% CI (-47.43~-6.18), P<0.01]; the creatine kinase isoenzyme MB (CK-MB) levels were (21.64±10.76) and (26.71±14.48)U·L-1, respectvely [OR=-4.19, 95% CI (-6.70~-1.67), P<0.001]were significantly better than those of . There was no statistically significant difference in the levels of lactate dehydrogenase (LDH) and cardiac troponin Ⅰ (cTnⅠ) of L-carnitine compared with the control group (all P>0.05).
The effectiveness of levocarnitine in the treatment of myocardial damage is relatively good, and there are no obvious adverse reactions.
PDF
196
40
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |
关闭全屏
No. 86 Xueyuan South Road, Haidian District, Beijing
010-62199257
qkjq@cast.org.cn
Copyright © 2025 China Association for Science and Technology. All rights reserved. For all open access content, the relevant licensing terms apply.
Sponsored by the Office of the Leading Group for Cybersecurity and Informatization of CAST, and supported by Science and Technology Review Publishing House
